Trials / Terminated
TerminatedNCT02764151
First in Patient Study for PF-06840003 in Malignant Gliomas
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06840003 IN PATIENTS WITH MALIGNANT GLIOMAS
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06840003 | Daily Oral PF-06840003 |
Timeline
- Start date
- 2016-09-09
- Primary completion
- 2018-12-26
- Completion
- 2018-12-26
- First posted
- 2016-05-06
- Last updated
- 2020-01-27
- Results posted
- 2020-01-27
Locations
14 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02764151. Inclusion in this directory is not an endorsement.